Related Experiment Videos
Adrenocortical carcinoma: a single institution experience
Fernando Gomez-Rivera1, Heriberto Medina-Franco, Jorge E Arch-Ferrer
1Section of Surgical Oncology, Department of Surgery, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA.
The American Surgeon
|March 11, 2005
Summary
Adrenocortical carcinoma (ADCC) is a rare endocrine tumor. Surgical resection improves survival, but advanced stage, metastasis, and positive margins indicate a poor prognosis.
Area of Science:
- Endocrinology
- Oncology
- Surgical Pathology
Background:
- Adrenocortical carcinoma (ADCC) is a rare and aggressive endocrine malignancy.
- Surgical resection is the primary treatment modality for ADCC.
- Understanding prognostic factors is crucial for patient management.
Purpose of the Study:
- To analyze patient and pathologic factors influencing survival in ADCC.
- To identify predictors of poor prognosis in adrenocortical carcinoma.
Main Methods:
- Retrospective review of medical records for 17 ADCC patients (1990-2000).
- Kaplan-Meier survival analysis was employed.
- Key factors analyzed included age, tumor stage, metastasis, and treatment approach.
Main Results:
- Median survival varied significantly by stage: 67 months (Stage II), 13 months (Stage III), and 3 months (Stage IV).
- Older age, distant metastasis, nonoperative management, positive surgical margins, advanced stage, and venous invasion were linked to worse survival.
- No operative mortality was observed in the surgically treated cohort.
Conclusions:
- Survival for adrenocortical carcinoma remains poor.
- Prognosis is significantly influenced by disease stage, surgical margin status, vascular invasion, and patient age.
- Early diagnosis and complete surgical resection are critical for improving outcomes in ADCC.